SIMPTOMATIK COVID-19 BEMORLARIDA JONLANTIRISH BO'LIMGA YOTQIZILISH XAVF OMILLARI: 1511 BEMORNING RETROSPEKTIV TAHLILI (TOSHKENT, 2020)

Baxodir Raximov; Erkin Sultonov; Baxtiyor Shodmonov

Authors

Baxodir Raximov Toshkent davlat tibbiyot universiteti, Atrof muhi gigiyeasi kafedrasi dotsenti, t.f.d., Toshkent sh., O‘zbekiston Author
Erkin Sultonov Toshkent davlat tibbiyot universiteti, Atrof muhi gigiyeasi kafedrasi asisstenti, Toshkent sh., O‘zbekiston Author
Baxtiyor Shodmonov Toshkent davlat tibiyot universiteti Chirchiq filiali O’quv-uslubiy boshqarma boshlig’i, Chirchiq sh., O‘zbekiston Author

Keywords:

COVID-19, statisonar bo’lim, xavf omillari, jonlantirish bo’lim, klinik xususiyatlar

Abstract

Ushbu tadqiqot 2020-yilning aprel–avgust oylarida Toshkent davlat tibbiyot universistetining ko'p tarmoqli klinikasida COVID-19 tashxisi bilan yotqizilgan 1511 simptomatik bemorning klinik xususiyatlarini va jonlantirish bo’limiga yotqizilish xavf omillarini aniqlashga qaratilgan bitta markazli retrospektiv tadqiqotdir. Simptomatik bemorlar statisonar bo’limi (n=1382) va jonlantirish bo’limi (n=129) guruhlarga bo'linib taqqoslandi.

Jonlantirish bo’limi guruhida yosh kattaroq (me'dian 56 yosh), qo'shimcha kasalliklar (ishemik yurak kasalligi, qandli diabet, gipertoniya) ko'proq va laboratoriya ko'rsatkichlari og'irroq bo'ldi. Binar logistik regressiya tahlili shuni ko'rsatdiki, yosh, qo'shimcha kasalliklar (OR=15,1), ishemik yurak kasalligi (OR=15,6), gipertenziv yurak kasalligi (OR=13,3), qandli diabet (OR=4,6), nafas qisishi (OR=5,7), pnevmoniya (OR=3,3), WBC va HGB o'zgarishlari jonlantirish bo’limiga yotqizilishning mustaqil xavf omillari hisoblanadi. Jonlantirish bo’limi guruhidagi o'lim ko'rsatkichi 29,5% ni tashkil etdi. Natijalar COVID-19 bilan og'ir kasallangan bemorlarni erta aniqlash va xavf guruhlarini ajratishda muhim ahamiyat kasb etadi.

Downloads

Download data is not yet available.

References

1. Jain V, Yuan JM. Predictive symptoms and comorbidities for severe COVID-19 and intensive care unit admission: a systematic review and meta-analysis. Int J Public Health. 2020;65(5):533-546.

2. Immovilli P, Morelli N, Antonucci E, et al. COVID-19 mortality and Jonlantirish bo’limi admission: the Italian experience. Crit Care. 2020;24(1):228.

3. Zhao Z, Chen A, Hou W, et al. Prediction model and risk scores of Jonlantirish bo’limi admission and mortality in COVID-19. PLoS One. 2020;15(7):e0236618.

4. Solmaz I, Ozcaylak S, Alakus OF, et al. Risk factors affecting Jonlantirish bo’limi admission in COVID-19 patients. Int J Clin Pract. 2021;75(3):e13803.

5. Interim guidelines for the management of patients infected with COVID-19 (6th ed.). The Ministry of Health of the Republic of Uzbekistan. 2020.

6. Responding to the COVID-19 pandemic: WHO's action in countries, territories and areas. Geneva: WHO; 2021.

7. Correa TD, Midega TD, Timenetsky KT, et al. Clinical characteristics and outcomes of COVID-19 patients admitted to the intensive care unit during the first year of the pandemic in Brazil. Einstein (Sao Paulo). 2021;19:eAO6739.

8. Immovilli P, Morelli N, Antonucci E, et al. COVID-19 mortality and Jonlantirish bo’limi admission: the Italian experience. Crit Care. 2020;24(1):228.

9. Grasselli G, Zangrillo A, Zanella A, et al. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to Jonlantirish bo’limis of the Lombardy Region, Italy. JAMA. 2020;323(16):1574-1581.

10. Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;382(18):1708-1720.

11. Alhumaid S, Al Mutair A, Al Alawi Z, et al. Clinical features and prognostic factors of intensive and non-intensive 1014 COVID-19 patients: an experience cohort from Alahsa, Saudi Arabia. Eur J Med Res. 2021;26(1):47.

12. Machado-Alba JE, Valladales-Restrepo LF, Machado-Duque ME, et al. Factors associated with admission to the intensive care unit and mortality in patients with COVID-19, Colombia. PLoS One. 2021;16(11):e0260169.

13. Wang F, Yang Y, Dong K, et al. Clinical Characteristics of 28 Patients with Diabetes and Covid-19 in Wuhan, China. Endocr Pract. 2020;26(6):668-674.

14. Wiersinga WJ, Rhodes A, Cheng AC, et al. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. JAMA. 2020;324(8):782-793.

15. Yang J, Wu K, Ding A, et al. Clinical characteristics, treatment, and prognosis of 74 2019 novel coronavirus disease patients in Hefei: A single-center retrospective study. Medicine (Baltimore). 2021;100(21):e25645.